EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Anaerobic Antibiotic Coverage in Aspiration Pneumonia and the Associated Benefits and Harms

Anthony D Bai, Siddhartha Srivastava, Geneviève C Digby, Vincent Girard, Fahad Razak, Amol A Verma

CHEST · 2024-07 · 166 (1) · 39-48

DOI: 10.1016/j.chest.2024.02.025 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift CHEST, 2024-07. Verfasst von Anthony D Bai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Queen's University, Kingston, ON, Canada. Electronic address: tony.bai@queensu.ca. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Hospital Mortality, Pneumonia, Aspiration. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Antibiotics with extended anaerobic coverage are used commonly to treat aspiration pneumonia, which is not recommended by current guidelines. RESEARCH QUESTION: In patients admitted to hospital for community-acquired aspiration pneumonia, does a difference exist between antibiotic therapy with limited anaerobic coverage (LAC) vs antibiotic therapy with extended anaerobic coverage (EAC) in terms of in-hospital mortality and risk of Clostridioides difficile colitis? STUDY DESIGN AND METHODS: We conducted a multicenter retrospective cohort study across 18 hospitals in Ontario, Canada, from January 1, 2015, to January 1, 2022. Patients were included if the physician diagnosed aspiration pneumonia and prescribed guideline-concordant first-line community-acquired pneumonia parenteral antibiotic therapy to the patient within 48 h of admission. Patients then were categorized into the LAC group if they received ceftriaxone, cefotaxime, or levofloxacin. Patients were categorized into the EAC group if they received amoxicillin-clavulanate, moxifloxacin, or any of ceftriaxone, cefotaxime, or levofloxacin in combination with clindamycin or metronidazole. The primary outcome was all-cause in-hospital mortality. Secondary outcomes included incident C difficile colitis occurring after admission. Overlap weighting of propensity scores was used to balance baseline prognostic factors. RESULTS: The LAC and EAC groups included 2,683 and 1,316 patients, respectively. In hospital, 814 patients (30.3%) and 422 patients (32.1%) in the LAC and EAC groups died, respectively. C difficile colitis occurred in five or fewer patients (≤ 0.2%) and 11 to 15 patients (0.8%-1.1%) in the LAC and EAC groups, respectively. After overlap weighting of propensity scores, the adjusted risk difference of EAC minus LAC was 1.6% (95% CI, -1.7% to 4.9%) for in-hospital mortality and 1.0% (95% CI, 0.3%-1.7%) for C difficile colitis. INTERPRETATION: We found that extended anaerobic coverage likely is unnecessary in aspiration pneumonia because it was associated with no additional mortality benefit, only an increased risk of C difficile colitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsHospital MortalityPneumonia, AspirationHumansMaleRetrospective StudiesFemaleAgedOntarioMiddle AgedAged, 80 and overCommunity-Acquired InfectionsClostridium InfectionsBacteria, AnaerobicClostridioides difficile

Stichwörter der Autor:innen

antibiotic treatmentaspiration pneumoniamortality

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, Queen's University, Kingston, ON, Canada. Electronic address: tony.bai@queensu.ca.
  • Division of General Internal Medicine, Department of Medicine, Queen's University, Kingston, ON, Canada.
  • Division of Respirology, Department of Medicine, Queen's University, Kingston, ON, Canada.
  • Internal Medicine Residency Program, Department of Medicine, Queen's University, Kingston, ON, Canada.
  • Department of Medicine, University of Toronto, Toronto, ON, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada; Li Ka Shing Knowledge Institute, St. Michael's Hospi…

Zitieren

APA

Bai, A. D., Srivastava, S., Digby, G. C., Girard, V., Razak, F., & Verma, A. A. (2024). Anaerobic Antibiotic Coverage in Aspiration Pneumonia and the Associated Benefits and Harms. CHEST, 166(1), 39-48. https://doi.org/10.1016/j.chest.2024.02.025

Vancouver

Bai AD, Srivastava S, Digby GC, Girard V, Razak F, Verma AA. Anaerobic Antibiotic Coverage in Aspiration Pneumonia and the Associated Benefits and Harms. CHEST. 2024;166(1):39-48. doi:10.1016/j.chest.2024.02.025

BibTeX
@article{Bai2024,
  author = {Bai, Anthony D and Srivastava, Siddhartha and Digby, Geneviève C and Girard, Vincent and Razak, Fahad and Verma, Amol A},
  title = {Anaerobic Antibiotic Coverage in Aspiration Pneumonia and the Associated Benefits and Harms},
  journal = {CHEST},
  year = {2024},
  volume = {166},
  number = {1},
  pages = {39--48},
  doi = {10.1016/j.chest.2024.02.025}
}
Kostenlos starten →